News Merck MS tablet set for wider use by NHS in England Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.
R&D Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl... Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
